Cargando…

Integration of cell therapies and bispecific antibodies into the treatment pathway of relapsed diffuse large B-cell lymphoma

Detalles Bibliográficos
Autores principales:	Rampotas, Alexandros, Sangha, Gina, Collins, Graham P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558790/ https://www.ncbi.nlm.nih.gov/pubmed/34733463 http://dx.doi.org/10.1177/20406207211053120

Ejemplares similares

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era
por: González Barca, Eva
Publicado: (2022)

Treatments for Relapsed-Refractory Diffuse Large B-cell Lymphoma: A Preliminary Evaluation of the Place in Therapy of Glofitamab, a Bispecific Monoclonal Antibody
por: Messori, Andrea, et al.
Publicado: (2022)

Enhancing the antitumor potency of T cells redirected by bispecific antibodies
por: Chang, Chien-Hsing, et al.
Publicado: (2017)

Novel, First-in-Human, Oral PCLX-001 Treatment in a Patient with Relapsed Diffuse Large B-Cell Lymphoma
por: Sangha, Randeep, et al.
Publicado: (2022)

P1187: SAFETY AND EFFICACY OF ANTICD20-CD3 BISPECIFIC T-CELL ENGAGING ANTIBODIES IN THE MANAGEMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SYSTEMATIC REVIEW OF CLINICAL TRIALS
por: Rahman, Mansoor, et al.
Publicado: (2023)

Management of relapsed-refractory diffuse large B cell lymphoma
por: Raut, Lalit S., et al.
Publicado: (2014)

Diffuse Large B Cell Lymphoma with Extensive Cutaneous Relapse
por: Malkan, Umit Yavuz, et al.
Publicado: (2015)

Mutational Evolution in Relapsed Diffuse Large B-Cell Lymphoma
por: Nijland, Marcel, et al.
Publicado: (2018)

Intensified therapy in diffuse large B-cell lymphoma
por: Novo, Mattia, et al.
Publicado: (2017)

Diffuse large B-cell lymphoma: the stuff of cell-of-origin and microenvironment
por: Pileri, Stefano A., et al.
Publicado: (2019)

Editorial on “Cell Therapy, Bispecific Antibodies and Other Immunotherapies against Cancer”
por: Golubovskaya, Vita
Publicado: (2023)

Relapse in stage I(E) diffuse large B‐cell lymphoma
por: Nijland, Marcel, et al.
Publicado: (2017)

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Harris, Leonard Jeff, et al.
Publicado: (2020)

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020)

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)

Neurolymphomatosis as a manifestation of relapsed diffuse large B‐cell lymphoma
por: Okamura‐Shiki, Ikue, et al.
Publicado: (2022)

Immunotherapy of Acute Lymphoblastic Leukemia and Lymphoma With T Cell–Redirected Bispecific Antibodies
por: Lussana, Federico, et al.
Publicado: (2021)

Intraocular lymphoma as relapse after chemotherapy for primary breast diffuse large B-cell lymphoma
por: Matsuo, Toshihiko, et al.
Publicado: (2018)

Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma
por: Desai, Sanjal H., et al.
Publicado: (2022)

Presentation of Diffuse Large B-Cell Lymphoma Relapse as a Penile Mass
por: Öneç, Birgül, et al.
Publicado: (2016)

Relapsed Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type
por: Wu, Shaohua, et al.
Publicado: (2017)

A diffuse large B cell lymphoma emerging with breast cancer relapse
por: Karismaz, Abdulkadir, et al.
Publicado: (2018)

Efficacy of salvage radiotherapy for relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Shu-Bei, et al.
Publicado: (2019)

Cytomegalovirus lymphadenitis mimicking a relapsed diffuse large B‐cell lymphoma
por: Delaye, Matthieu, et al.
Publicado: (2022)

The clinical challenge of relapsed diffuse large B-cell lymphoma with disseminated infection
por: Goh, Suek Chern, et al.
Publicado: (2023)

CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma
por: Quintás-Cardama, Alfonso
Publicado: (2018)

Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)

Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma
por: Galaznik, Aaron, et al.
Publicado: (2018)

T-Cell Engaging Antibodies in Diffuse Large B Cell Lymphoma—An Update
por: Balendran, Shalini, et al.
Publicado: (2023)

Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses
por: Broséus, Julien, et al.
Publicado: (2016)

Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
por: Bari, Alessia, et al.
Publicado: (2022)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
por: Vacirca, Jeffrey L., et al.
Publicado: (2013)

MicroRNAs as predictors for CNS relapse of systemic diffuse large B-cell lymphoma
por: Pillar, Nir, et al.
Publicado: (2017)

CNS relapse of diffuse large B cell Lymphoma A single centre experience
por: Nazir, Adil, et al.
Publicado: (2017)

Diffuse Large B-Cell Lymphoma Relapsing in Leukaemic Phase Presenting as Acute Leukaemia
por: Balasubramanian, Priyavadhana, et al.
Publicado: (2019)

How I manage patients with relapsed/refractory diffuse large B cell lymphoma
por: Gisselbrecht, Christian, et al.
Publicado: (2018)

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
por: Lee, Boram, et al.
Publicado: (2021)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
por: Yuan, Xianggui, et al.
Publicado: (2022)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
por: Kong, Xiaoshuang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j0dfr4ke32n6onapgn1rumvh6u